Day One Biopharmaceuticals, Inc.

    Jurisdiction
    United States
    ISIN
    US23954D1090 (DAWN)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    5 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    5 / 7

    Profile

    Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €160.99M
    Gross margin
    94.0%
    EBIT
    -€95.87M
    EBIT margin
    -59.5%
    Net income
    -€81.51M
    Net margin
    -50.6%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €185.40M +15.2% -€65.68M -19.4%
    €278.87M +50.4% €3.47M -105.3%
    €372.50M +33.6% €70.83M +1,940.0%

    Dividends

    No dividend payouts

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Bender Jeremy CHIEF EXECUTIVE OFFICER -16K $6.77 -$108.71K
    Dubow Adam Gen Counsel & Secretary -4.4K $6.77 -$29.55K
    Merendino Lauren Chief Commercial Officer -3.8K $6.77 -$25.50K
    York Charles N II COO and CFO -4.1K $6.77 -$27.80K

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 348K $2.76M +105K Buy

    Add to watchlist

    Notifications